Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 191 clinical trials
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

This trial looks at how well a distress reduction intervention, called "Being Present", works to improve the quality of life of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs

chronic phase chronic myeloid leukemia
leukemia
tyrosine
  • 0 views
  • 15 Apr, 2021
  • 1 location
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

myeloproliferative neoplasms (MPN), and chronic or accelerated phase MPN-unclassifiable (MPN-U) and MDS-MPN. Blast crisis phase of MPNs are considered secondary AML and will be included in the AML cohort.

refractory acute myeloid leukemia (aml)
blast cells
blast crisis
  • 0 views
  • 24 Jul, 2021
  • 9 locations
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm.

myelodysplastic/myeloproliferative neoplasm
azacitidine
myeloproliferative disorder
sgi-110
decitabine
  • 17 views
  • 20 Mar, 2021
  • 5 locations
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory leukemia or other refractory myeloid malignanies is poor. One of the approaches to augment graft-versus-leukemia effect the use of post-transplantation bendamustine in graft-versus-host disease prophylaxis. Despite high frequency of responses and durable remissions after this approach majority of patients …

cyclophosphamide
myelodysplastic syndromes
chronic myeloid leukemia
myeloid leukemia
leukemia
  • 0 views
  • 04 Jul, 2021
  • 1 location
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

. 4. Myeloproliferative disorder (MPD) with eosinophilia, eosinophilic leukemia or chronic myelomonocytic leukemia [myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS

myelodysplastic/myeloproliferative neoplasm
bone marrow transplant
leukemia
myelodysplastic syndromes
chronic myelomonocytic leukemia
  • 10 views
  • 07 Nov, 2020
  • 14 locations
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given

induction chemotherapy
glomerular filtration rate
cytarabine
aspirin
myeloproliferative disorder
  • 12 views
  • 12 Jun, 2021
  • 2 locations
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping

myeloproliferative disorder
chronic myelomonocytic leukemia
procrit
TP53
growth factor
  • 0 views
  • 25 Jan, 2021
Salsalate Venetoclax and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of

myelodysplasia
myeloproliferative disorder
chronic myelomonocytic leukemia
myeloid leukemia
TP53
  • 0 views
  • 26 Jan, 2021
  • 1 location
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

(AML), respectively. The study team hypothesize that the combination of these agents in patients with MPN with an IDH2 mutation will improve the overall clinical response to therapy.

  • 0 views
  • 30 May, 2021
  • 11 locations
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and …

  • 0 views
  • 01 Apr, 2021
  • 6 locations